Skip to content

Ardelyx ARDX Number of Vested and Expected to Vest Options

Number of Vested and Expected to Vest Options at other companies

Mineralys Therapeutics, Inc. logo
Mineralys Therapeutics, Inc.MLYS
$32.3M+669%
Agios Pharmaceuticals logo
Agios PharmaceuticalsAGIO

Other financials

Income statement

See full
Revenue$94.5M+27.5%
Gross profit$89.7M+45.1%
Operating income-$32.8M+9.8%
Net income-$37.6M+8.6%
EPS (diluted)-$0.15+11.8%

Balance sheet

See full
Cash & equivalents$31.2M+1.3%
Total debt$208.3M+34.3%
Total equity$148.6M+2.0%
Total assets$504.5M+23.0%

Cash flow

See full
Operating cash flow-$32.2M+16.2%
CapEx$69.0K-78.8%
Free cash flow-$32.3M+16.7%

Valuation

See full
Market cap$1.53B+25.5%
Enterprise value$1.71B+27.1%
P/S3.6×+0.2×

Profitability

See full
Gross margin92.5%+7.9pp
Operating margin-25.4%
Net margin-13.6%
FCF margin-40.9%

Returns & leverage

See full
Return on equity-39.5%
Debt / equity1.4×+0.3×
Current ratio3.5×-0.6×

Where this comes from

Reported directly by Ardelyx in its filing.

Tagged under the XBRL concept us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue.

The official record: Ardelyx’s 10-K, filed February 19, 2026, on SEC EDGAR. View the filing →

Ask your AI about Ardelyx's number of vested and expected to vest options.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Ardelyx's number of vested and expected to vest options?
Ardelyx (ARDX) reported number of vested and expected to vest options of $37.41M in Q4 2025.
How has Ardelyx's number of vested and expected to vest options changed year-over-year?
Ardelyx's number of vested and expected to vest options increased by 17.5% year-over-year, from $31.83M to $37.41M.
What does number of vested and expected to vest options mean?
The total number of share-based payment options that have either vested or are expected to vest based on current performance and service conditions. This figure represents the potential future dilution of existing shareholders through equity-based compensation. It is a vital metric for assessing the company's total equity incentive overhang and management's compensation structure.